BRM/BRG1 ATP Inhibitor-1 (compound 14) (oral administration, 7.5 or 20 mg/kg, everyday, 3 weeks) can inhibit tumor growth and inhibit KRT80 expression in a dose-dependent manner[1].
| Animal Model: | Female athymic nude mice with RERF-LC-AI tumor xenografts[1] |
| Dosage: | 7.5 mg/kg, 20 mg/kg |
| Administration: | Oral administration; everyday; 3 weeks |
| Result: | Inhibited tumor growth by 21% and 55% at doses of 7.5 mg/kg and 20 mg/kg, respectively.
Inhibited KRT80 expression by up to 90% at 20 mg/kg for 7 hours after administration.
|
